Diabetes, weight loss drug companies growth far from over, says ClearBridge analyst

ClearBridge research analyst Marshall Gordon sits down with InvestmentNews anchor Gregg Greenberg to discuss the rise of new diabetes and weight-loss drugs, as well as the best ways to invest in this burgeoning sector.
  • Aug 30, 2023
More: IN THE NASDAQ
SPY keeps gathering assets even as ETF world evolves 

SPY keeps gathering assets even as ETF world evolves 

The election or the Fed? Which is the bigger market risk going forward?

The election or the Fed? Which is the bigger market risk going forward?

Here’s why technology is the new key to estate planning

Here’s why technology is the new key to estate planning